Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do SciELO, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Correlation between CSF biomarkers of Alzheimer’s disease and global cognition in a psychogeriatric clinic cohort

Texto completo
Autor(es):
Márcia Radanovic ; Carlos A. Oshiro ; Thiago Q. Freitas ; Leda L. Talib ; Orestes V. Forlenza
Número total de Autores: 5
Tipo de documento: Artigo Científico
Fonte: Revista Brasileira de Psiquiatria; n. ahead, p. -, 2019.
Resumo

Objective: The relationship between biomarkers of amyloid-beta aggregation (Aβ1-42) and/or neurodegeneration (Tau protein) in cerebrospinal fluid (CSF) and cognitive decline is still unclear. We aimed to ascertain whether CSF biomarkers correlate with cognitive performance in healthy and cognitively impaired subjects, starting from clinical diagnoses. Methods: We tested for correlation between CSF biomarkers and Mini-Mental State Examination (MMSE) scores in 208 subjects: 54 healthy controls, 82 with mild cognitive impairment (MCI), 46 with Alzheimer’s disease (AD), and 26 with other dementias (OD). Results: MMSE correlated weakly with all CSF biomarkers in the overall sample (r = 0.242, p < 0.0006). Aβ1-42 and MMSE correlated weakly in MCI (r = 0.247, p = 0.030), and moderately in OD (r = 0.440, p = 0.027). t-Tau showed a weak inverse correlation with MMSE in controls (r = -0.284, p = 0.043) and MCI (r = -0.241, p = 0.036), and a moderate/strong correlation in OD (r = 0.665), p = 0.0003). p-Tau correlated weakly with MMSE in AD (r = -0.343, p = 0.026) and moderately in OD (r = -0.540, p = 0.0005). The Aβ1-42/p-Tau ratio had a moderate/strong correlation with MMSE in OD (r = 0.597, p = 0.001). Conclusion: CSF biomarkers correlated best with cognitive performance in OD. t-Tau correlated weakly with cognition in controls and patients with MCI. In AD, only p-Tau levels correlated with cognitive performance. This pattern, which has been reported previously, seems to indicate that CSF biomarkers might not be reliable as indicators of disease severity. (AU)

Processo FAPESP: 09/52825-8 - Neurobiologia da doença de Alzheimer: marcadores de risco, prognóstico e resposta terapêutica
Beneficiário:Wagner Farid Gattaz
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 16/01302-9 - Identificação das vias direta e indireta da inibição da glicogênio sintase kinase 3B pelo lítio em cultura de neurônios
Beneficiário:Vanessa de Jesus Rodrigues de Paula
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 14/14211-6 - Comprimento telomérico no sistema nervoso central de um modelo de Doença de Alzheimer tratado com lítio
Beneficiário:Giancarlo de Mattos Cardillo
Linha de fomento: Bolsas no Brasil - Mestrado